• Click and Discover Platform set to buck trends in Drug Development
    Professor John Overington

News & Views

Click and Discover Platform set to buck trends in Drug Development

Aug 31 2021

Bioinformatics has seen the emergence of the first no-code, pay as you go drug discovery platform that simplifies access to AI models for SME’s at the click of a button. Developed by Chief.AI in partnership with the Medicines Discovery Catapult (MDC), the cloud-based system provides access to information, skills and resources along with production infrastructure and analytics for models without the need for substantial and expensive internal IT capabilities.
Supported by an Innovate UK grant, the project is based on the development of models by MDC, with Chief.AI providing the orchestration engine.
The ability to utilise AI in this way could provide huge advantages in terms of costs and timing as well as making efficient use of resources. For example, it could be used to analyse and predict the behaviour of molecules in the human body much earlier than traditional methods, which financially could save billions in research and development.
“As an orchestrator of AI, we are delighted to be able to make access to AI easier and more effective for healthcare providers around the world. Artificial intelligence will prove to be a great force multiplier for data intensive applications such as drug discovery and diagnostics and with the help of the Medicines Discovery Catapult, Chief.AI is strategically poised to enable businesses around the world to connect to AI and reap these efficiencies seamlessly,” said Chief.AI founder Waqar Ali.

Professor John P. Overington, Chief Informatics Officer, Medicines Discovery Catapult, added: “This is a very exciting time for drug discovery. The development and utilisation of AI has been something that the industry has needed to propel that next step forward, and with Chief.AI it is now possible. AI is going to be something that will permeate across all aspects of society and business in the years to come and it is wonderful that we are able to offer this platform to UK SMEs, providing them with information and expertise which otherwise would have been inaccessible.”

More information online

Digital Edition

ILM 49.5 July

July 2024

Chromatography Articles - Understanding PFAS: Analysis and Implications Mass Spectrometry & Spectroscopy Articles - MS detection of Alzheimer’s blood-based biomarkers LIMS - Essent...

View all digital editions


ADLM 2024

Jul 28 2024 San Diego, CA USA

InaLab 2024

Jul 30 2024 Jakarta, Indonesia


Jul 31 2024 Chengdu, China

ACS National Meeting - Fall 2024

Aug 18 2024 Denver, CO, USA


Aug 25 2024 Copenhagen, Denmark

View all events